Patents by Inventor Mark Robert Barvian

Mark Robert Barvian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
    Patent number: 6982260
    Abstract: This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8-alkyl-2-arylamino-quinazoline 2,7-diamines that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provide useful intermediates generated during the production of the quinazoline compounds.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: January 3, 2006
    Assignee: Warner-Lambert Company
    Inventors: Mark Robert Barvian, Ellen Myra Dobrusin, James Stanley Kaltenbronn, Peter L. Toogood, Roy Thomas Winters, Inderjit S. Sidhu, Rajeshwar Singh, Yadagiri Bathini, Ronald George Micetich
  • Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
    Patent number: 6972287
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well as new compounds of Formula (I).
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: December 6, 2005
    Assignee: Pfizer Inc.
    Inventors: Corinne Elizabeth Augelli-Szafran, Mark Robert Barvian, Christopher Franklin Bigge, Shelly Ann Glase, Shunichiro Hachiya, John Steven Kiely, Takenori Kimura, Yingjie Lai, Annette Theresa Sakkab, Mark James Suto, Larry Craswell Walker, Tomoyuki Yasunaga, Nian Zhuang
  • Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
    Publication number: 20040220235
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula I 1
    Type: Application
    Filed: June 2, 2004
    Publication date: November 4, 2004
    Inventors: Corinne Elizabeth Augelli-Szafran, Mark Robert Barvian, Christopher Franklin Bigge, Shelly Ann Glase, Shunichiro Hachiya, John Steven Kiely, Takenori Kimura, Yingjie Lai, Annette Theresa Sakkab, Mark James Suto, Lary Craswell Walker, Tomoyuki Yasunaga, Nian Zhuang
  • Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
    Patent number: 6498163
    Abstract: This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula I: and Formula II: where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and Z is carboxy. This invention also provides pharmaceutical formulations comprising a compound of Formula I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 24, 2002
    Assignee: Warner-Lambert Company
    Inventors: Diane Harris Boschelli, Annette Marian Doherty, Ali Fattaey, David William Fry, Susanne Andrea Trumpp-Kallmeyer, Zhipei Wu, Ellen Myra Dobrusin, Mark Robert Barvian
  • Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
    Patent number: 6150359
    Abstract: This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: November 21, 2000
    Assignee: Warner-Lambert Company
    Inventors: Mark Robert Barvian, William Alexander Denny, Ellen Myra Dobrusin, James Marino Hamby, Howard Daniel Hollis Showalter, Andrew Mark Thompson, Roy Thomas Winters, Zhipei Wu